A randomized, double-blind, placebo-controlled trial to assess the safety and tolerability of a respiratory syncytial virus (RSV) neutralizing monoclonal antibody (MK-1654) in healthy subjects

Authors
Category Primary study
JournalOpen Forum Infectious Diseases
Year 2018
This article has no abstract
Epistemonikos ID: 055f153b2e80f75e255d7fc4b0026be4cbe7a17e
First added on: Dec 20, 2022